Sienna Biopharmaceuticals (SNNA) IPO Opens Sharply Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
July 26, 2017 7:30 PM EDTWESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA) today announced the pricing of the Companys initial public offering of 4,333,333 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares of common stock are being offered by Sienna. The Company has also granted the underwriters a 30-day option to purchase from the Company an additional 650,000 shares of common stock at the initial public offering price, less the underwriting discount. Siennas common stock has been approved for listing... More
